Contents
Special Issue Topic

Integrated Approaches for Non-Small-Cell Lung Cancer

Guest Editors

Dr. Alessandro Morabito E-Mail

Director of Thoracic Medical Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy

Research Keywords: Lung cancer; target based agents; angiogenesis inhibitors; immunotherapy; clinical trials

Dr. Edoardo Mercadante E-Mail

Director of Thoracic Surgery Unit, National Cancer Institute IRCCS ”Pascale Foundation”, Naples, Italy

About the Special lssue

The treatment landscape of patients with non-­small-­cell lung cancer (NSCLC) has dramatically changed in recent years, thanks to the improvement in the knowledge of the biology of NSCLC, the discovery of targetable oncogenic drivers, the positive results obtained with immunotherapy in different settings (advanced, locally advanced, adjuvant, neoadjuvant) and the optimal integration of surgery, radiotherapy and systemic treatments. Furthermore, thanks to the advent of technology, surgical minimally invasive treatments (Robotic and Thoracoscopic) are always less traumatic, thus, increasing the number of surgical candidates, even in fragile and with co-morbidities patients.

For NSCLC patients with early and locally advanced disease a through therapeutic revolution is currently ongoing and a multidisciplinary approach is mandatory. This Special Issue will highlight the current state of treatment of early and locally advanced NSCLC patients, focusing on the approved indications of surgery, radiotherapy and systemic treatments, including chemotherapy, immunotherapy and targeted based agents. Moreover, the strategies to improve the results obtained to date and the challenge to face resistance disease will be discussed. Finally, the role of liquid biopsy in this setting and its potential implementation will be evaluated.

The possible topics could be (but not limited to) :

  • The role of radioterapy in early stage NSCLC

  • Advancement in radiotherapy for locally advanced NSCLC

  • New surgical approaches for early stage NSCLC

  • Role of surgery for locally advanced NSCLC

  • Immunotherapy for locally advanced NSCLC

  • Target based agents for oncogene addicted locally advanced NSCLC

  • The role of liquid biopsy in early stage NSCLC

  • Advancement in the treatment of locally advanced NSCLC

  • Minimally invasive surgery and its efficacy on lymphadenectomy

  • Activity of a Lung Cancer MDT: benefits and barriers

Keywords: Early stage NSCLC; locally advanced NSCLC; thoracic radiotherapy; thoracic surgery; adjuvant treatment; liquid biopsy; immunotherapy

Published Articles

Open Access Review
A narrative review on perioperative systemic therapy in non-small cell lung cancer
Robert Hsu ... David J. Benjamin
Published: July 26, 2024 Explor Target Antitumor Ther. 2024;5:931–954
2023 34 3
Open Access Review
Current status of molecular diagnostics for lung cancer
Evgeny N. Imyanitov ... Sergey V. Orlov
Published: June 27, 2024 Explor Target Antitumor Ther. 2024;5:742–765
2341 68 3
Open Access Review
Improving the quality of patient care in lung cancer: key factors for successful multidisciplinary team working
Alessandro Morabito ... Giacomo Pascarella
Published: March 21, 2024 Explor Target Antitumor Ther. 2024;5:260–277
3556 70 3
Open Access Mini Review
Management of stage III non-small-cell lung cancer: rays of hope
Floryane Kim ... Alex Friedlaender
Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:85–95
3696 103 1
Open Access Review
Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
Gerhard Hamilton ... Barbara Rath
Published: October 26, 2023 Explor Target Antitumor Ther. 2023;4:1027–1038
2185 22 2